Indications
Therapeutic Asset Ratings
9,920 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Pembrolizumab
Skin Basal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
P1
CC
(43)
Pembrolizumab
Urinary Bladder Small Cell Neuroendocrine Carcinoma
Jonsson Comprehensive Cancer Center
P1
CC
(43)
Pembrolizumab
Bone Sarcoma
University of Southern California
P1
CC
(43)
Pembrolizumab
Thymic Carcinoma
Novartis Pharmaceuticals
P1
CC
(43)
Pembrolizumab
Clear Cell Sarcoma
Seattle Children's Hospital
P1
CC
(43)
Pembrolizumab
Skin Neoplasm
Memorial Sloan Kettering Cancer Center
P1
CC
(43)
Pembrolizumab
Dedifferentiated Liposarcoma
Epkin
P1
CC
(43)
Pembrolizumab
Desmoplastic Small Round Cell Tumor
Seattle Children's Hospital
P1
CC
(43)
Pembrolizumab
Epstein-Barr Virus-Associated Carcinoma
Viracta Therapeutics, Inc.
P1
CC
(43)
Pembrolizumab
Epstein-Barr Virus-Associated Gastric Carcinoma
Viracta Therapeutics, Inc.
P1
CC
(43)
Pembrolizumab
Epstein-Barr Virus-Associated Mesenchymal Tumor
Viracta Therapeutics, Inc.
P1
CC
(43)
Pembrolizumab
Ewing Sarcoma
Seattle Children's Hospital
P1
CC
(43)
Pembrolizumab
Extramammary Paget Disease
Memorial Sloan Kettering Cancer Center
P1
CC
(43)
Pembrolizumab
Digestive System Cancer
M.D. Anderson Cancer Center
P1
CC
(43)
Pembrolizumab
Hematopoietic And Lymphoid Cell Neoplasm
City of Hope Medical Center
P1
CC
(43)
Pembrolizumab
Hepatoblastoma
Seattle Children's Hospital
P1
CC
(43)
Pembrolizumab
Leiomyosarcoma
Epkin
P1
CC
(43)
Pembrolizumab
Lymphoid Leukemia
Dana-Farber Cancer Institute
P1
CC
(43)
Pembrolizumab
Male Reproductive Organ Cancer
M.D. Anderson Cancer Center
P1
CC
(43)
Pembrolizumab
Malignant Mesothelioma
M.D. Anderson Cancer Center
P1
CC
(43)
Pembrolizumab
Myxofibrosarcoma
Epkin
P1
CC
(43)
Pembrolizumab
Neuroblastoma
Seattle Children's Hospital
P1
CC
(43)
Pembrolizumab
Mouth Disorder
VLP Therapeutics
P1
CC
(43)
Pembrolizumab
Oral Cavity Carcinoma
VLP Therapeutics
P1
CC
(43)
Pembrolizumab
Osteosarcoma
Valo Therapeutics Oy
P1
CC
(43)
Showing 3776 to 3800 of 9,920 assets
Previous
Page 152 of 397
Next
